ArticleCureus2025
Post-COVID Myoclonus-Ataxia Syndrome: A Case Report of Successful Recovery With Intravenous Immunoglobulin (IVIG) Treatment.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 virus responsible for COVID-19 can trigger multisystemic syndromes that persist beyond the acute infection. Among these, neurological complications have become increasingly recognized. Reported outcomes include headaches, encephalitis, encephalopathy, anosmia, ageusia, Guillain-Barré syndrome, and skeletal muscle involvement such as myalgia and myasthenia gravis. Myoclonus-ataxia syndrome has emerged as a rare post-infectious complication. We describe an immunocompetent adult who developed post-COVID-19 myoclonus-ataxia with a distinct post-infectious timeline. The patient had minimal response to corticosteroids but experienced rapid and marked recovery with intravenous immunoglobulin (IVIG). Delayed access to IVIG due to insurance limitations prolonged disease progression. This case underscores the importance of individualized treatment strategies in post-COVID neurological syndromes and highlights the impact of systemic healthcare barriers. Given the rarity of this presentation and the variable treatment responses observed, this report contributes to the understanding of post-COVID neurological complications and their management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.